Company / Working Capital
CRISPR Therapeutics AG Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.8B
FY2025
5-year range
$1.7B / $2.3B
FY2021-FY2025
Trend
-0.7%
vs FY2024
Sector context
#24 of 215
Health Care
What the data says
CRISPR Therapeutics AG's working capital of $1.8B is higher than 89% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $234M in FY2017 to $2.3B in FY2021.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +2.5%. Top quartile in the Health Care sector.
Improved from $1.8B to $1.8B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +2.0%
- 5-Year CAGR
- +2.5%
- 10-Year CAGR
- -
Sector benchmark
+91.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.5%, indicating consistent growth.
- In FY2025, working capital decreased 0.7% year-over-year.
- Ranks #24 out of 215 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | -0.7% |
| FY2024 | $1.8B | +2.8% |
| FY2023 | $1.8B | +3.9% |
| FY2022 | $1.7B | -24.6% |
| FY2021 | $2.3B | +41.6% |
| FY2020 | $1.6B | +74.4% |
| FY2019 | $930.4M | +112.1% |
| FY2018 | $438.6M | +87.6% |
| FY2017 | $233.9M | -21.6% |
| FY2016 | $298.2M | +103.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026